OABI

OmniAb, Inc. (OABI) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $3.99 million exceeding expectations by 10.12%. The company has outperformed the S&P 500 by 182.7% year-to-date.

However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Drugs industry ranks in the top 36% of Zacks industries.

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.